Shire PLC (NASDAQ:SHPG) Shares Sold by ING Groep NV

ING Groep NV reduced its position in shares of Shire PLC (NASDAQ:SHPG) by 4.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,229 shares of the biopharmaceutical company’s stock after selling 487 shares during the period. ING Groep NV’s holdings in Shire PLC were worth $1,856,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. HPM Partners LLC acquired a new position in shares of Shire PLC during the first quarter worth about $1,534,000. Vanguard Group Inc. raised its position in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares during the last quarter. BlackRock Inc. raised its position in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares during the last quarter. Laurion Capital Management LP acquired a new position in shares of Shire PLC during the first quarter worth about $10,611,000. Finally, Atria Investments LLC raised its position in shares of Shire PLC by 32.6% in the second quarter. Atria Investments LLC now owns 1,648 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 405 shares during the last quarter. 20.22% of the stock is currently owned by institutional investors.

Shire PLC (NASDAQ SHPG) opened at 147.95 on Friday. Shire PLC has a 1-year low of $147.28 and a 1-year high of $209.22.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.53 by $0.20. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The firm had revenue of $3.75 billion during the quarter. During the same quarter in the previous year, the firm posted $3.38 EPS. The company’s revenue for the quarter was up 54.2% compared to the same quarter last year. On average, equities analysts expect that Shire PLC will post $14.91 EPS for the current fiscal year.

The company also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be paid a $0.1527 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is currently 40.63%.

COPYRIGHT VIOLATION WARNING: “[[title]]” was originally posted by [[site]] and is the sole property of of [[site]]. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at [[permalink]].

A number of equities analysts have issued reports on SHPG shares. Piper Jaffray Companies set a $159.00 target price on Shire PLC and gave the company a “hold” rating in a research report on Wednesday, July 26th. Zacks Investment Research lowered Shire PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Sanford C. Bernstein lowered Shire PLC from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $209.22 to $161.09 in a research report on Thursday, May 25th. BidaskClub lowered Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, HSBC Holdings plc lowered Shire PLC from a “hold” rating to a “reduce” rating in a research report on Friday, May 19th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $220.08.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.